Goldenwell Biotech(OTC) GWLL

Market Cap$69.30M

Since IPO (2022)+137%

5 YearN/A

1 Year+250%

1 Month-22%

$0.70

+0.00%

+0.00Today

Goldenwell Biotech last closing stock price
Metric	Price	Date
Last close	USD 0.70	2026-08-20

Goldenwell Biotech stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-9.09%	USD 0.77	2026-08-13
1 month	-22.22%	USD 0.90	2026-07-13
3 month	-29.65%	USD 1.00	2026-05-22
Year to date	-75.86%	USD 2.90	2025-12-29
1 year	+250%	USD 0.20	2025-05-16
3 year	+180%	USD 0.25	2023-07-26
Since inception	+137.29%	USD 0.30	2022-09-30

Goldenwell Biotech Financials at a Glance

Market Cap

$69.30M

Revenue (TTM)

$23.20K

Net Income (TTM)

-$262.21K

EPS (TTM)

-$0.00

P/E Ratio

-241.38

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.70

Volume

1,000

Open

$0.70

Price

$0.70

Volume

1,000

Open

$0.70

Previous Close

$0.70

Daily Range

$0.70 - $0.70

52-Week Range

$0.20 - $10.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.70

Volume

1,000

Open

$0.70

Previous Close

$0.70

Daily Range

$0.70 - $0.70

52-Week Range

$0.20 - $10.00

Estimated Earnings Date

N/A

GWLL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Goldenwell Biotech

Goldenwell Biotech, Inc. is a healthcare company focused on the development of nutraceutical and dietary supplements in the United States. The company is innovating products aimed at enhancing health and wellness, including specialized peptides and dietary supplements.

Products and Services

JI MAI, a bovine cardiac vascular active peptide
Double Proline AG, a 3D active collagen peptide drinkable cosmetic
Sugar Master, a dietary supplement for metabolic health

Growth Outlook

Market demand for dietary supplements is projected to grow significantly
Innovative product pipeline positions the company for future expansion
Strategic focus on health trends aligns with consumer preferences

Financial Highlights

Recent quarterly revenue of -$1,860 indicates ongoing challenges
Trailing twelve months (TTM) revenue shows a significant price-to-sales ratio of 1467.99
Cash reserves of $26,775 provide a buffer for operational needs

Goldenwell Biotech, Inc. operates in the medical and pharmaceutical industry, emphasizing the development of innovative health products. The company has a diverse product portfolio that includes specialized peptides aimed at improving cardiovascular health and skin aesthetics. Despite facing financial challenges, including negative revenue in recent quarters, the company is strategically positioned to capitalize on the growing demand for dietary supplements. The innovative product pipeline and alignment with health trends suggest potential for future growth. Financially, the company maintains a cash reserve that may support ongoing operations and development efforts. Investors may find interest in the company's unique offerings and market positioning within the health and wellness sector.

AI Generated • Aug 4, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

CEO

Shuang Liu

Website

www.goldenwellbiotech.com

Headquarters

Solon, OH 44139, US

GWLL Financials

Key Financial Metrics (TTM)

Gross Margin

107.83%

Operating Margin

-409.10%

Net Income Margin

-1130.45%

Return on Equity

89.25%

Return on Capital

N/A

Return on Assets

-904.85%

Earnings Yield

-0.41%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$69.30M

Shares Outstanding

99.00M

Volume

1.00K

Avg. Volume

49.016

Financials (TTM)

Gross Profit

$25.01K

Operating Income

-$94.89K

EBITDA

-$253.81K

Operating Cash Flow

-$25.90K

Capital Expenditure

$0.00

Free Cash Flow

-$25.90K

Cash & ST Invst.

$26.78K

Total Debt

$327.17K

Goldenwell Biotech Performance Analysis

Goldenwell Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 47,800	199.4%
2023	2023-12-31	USD 1,836	-96.2%
2024	2024-12-31	USD 139	-92.4%
2025	2025-12-31	USD 55	-60.4%

Goldenwell Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-33.3%
Q4	2025-12-31	-99.8%
Q1	2026-03-31	-3481.8%
Q2	2026-06-30	100.0%

Goldenwell Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.01	684.6%
2023	2023-12-31	USD -0.00	-88.2%
2024	2024-12-31	USD -0.00	8.3%
2025	2025-12-31	USD -0.00	130.8%

Goldenwell Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	66.7%
Q4	2025-12-31	-1900.0%
Q1	2026-03-31	90.0%
Q2	2026-06-30	-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$69.30M

N/A

Market Cap/Employee

$23.10M

N/A

Employees

N/A

Net Income

-$36.88K

-606.4%

EBITDA

-$34.78K

-1014.6%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$26.78K

-65.0%

Total Debt

$327.17K

+19.5%

Accounts Receivable

$0.00

N/A

Inventory

$174.75K

-0.0%

Long Term Debt

$327.17K

+19.5%

Short Term Debt

$0.00

N/A

Return on Assets

-9.05%

N/A

Return on Invested Capital

1.34%

N/A

Free Cash Flow

$59.38K

+0.0%

Operating Cash Flow

$59.38K

+0.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

GKSDFGrupo KUO, S.A.B. de C.V.

GKSDFGrupo KUO, S.A.B. de C.V.$1.90+0.00%

ARZTYAryzta AG

ARZTYAryzta AG$5.11+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.92+0.00%

WETOWetour Robotics

WETOWetour Robotics$5.48-0.04%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

INTCIntel

INTCIntel$89.51+0.00%

NVDANvidia

NVDANvidia$220.78+0.01%

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF$82.52-0.00%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$44.67+0.02%

Questions About GWLL

What is the current price of Goldenwell Biotech?

Goldenwell Biotech is trading at $0.70 per share.

What is the 52-week range for Goldenwell Biotech?

Over the past 52 weeks, Goldenwell Biotech has traded between $0.20 and $10.00.

How much debt does Goldenwell Biotech have?

As of the most recent reporting period, Goldenwell Biotech reported total debt of $327.17K.

How much cash does Goldenwell Biotech have on hand?

Goldenwell Biotech reported $11.14K in cash and cash equivalents in its most recent financial results.

What is Goldenwell Biotech’s dividend yield?

Goldenwell Biotech does not currently have a dividend yield.

Goldenwell Biotech(OTC) GWLL

Goldenwell Biotech Financials at a Glance

GWLL News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Goldenwell Biotech

GWLL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Goldenwell Biotech Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About GWLL

What is the current price of Goldenwell Biotech?

What is the 52-week range for Goldenwell Biotech?

How much debt does Goldenwell Biotech have?

How much cash does Goldenwell Biotech have on hand?

What is Goldenwell Biotech’s dividend yield?

Premium Investing Services